IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis
Titel:
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis
Auteur:
Balak, Deepak M.W. van Doorn, Martijn B.A. Arbeit, Robert D. Rijneveld, Rianne Klaassen, Erica Sullivan, Tim Brevard, Julie Thio, Hok Bing Prens, Errol P. Burggraaf, Jacobus Rissmann, Robert